Short communication: Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity

Circulation Research

Volumn 109, Issue 3, 2011, Pages 291-295

  Liu, Nian ^a   Denegri, Marco ^b   Ruan, Yanfei ^a   Avelino Cruz, José Everardo ^b   Perissi, Andrea ^b   Negri, Sara ^b   Napolitano, Carlo ^a   Coetzee, William A ^a   Boyden, Penelope A ^c   Priori, Silvia G ^a,b,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

genetics; ryanodine receptor; sodium channel; ventricular tachycardia

Indexed keywords

CALCIUM; FLECAINIDE; ISOPRENALINE; RYANODINE RECEPTOR 2; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL ISOLATION; CELL PERMEABILIZATION; CONTROLLED STUDY; DRUG MECHANISM; ELECTROCARDIOGRAM; HEART MUSCLE CELL; INTRACELLULAR MEMBRANE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM SIGNALING; DISEASE MODELS, ANIMAL; EXTRACELLULAR SPACE; FLECAINIDE; GENE KNOCK-IN TECHNIQUES; ISOPROTERENOL; MICE; MICE, MUTANT STRAINS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SODIUM CHANNELS; SYMPATHOMIMETICS; TACHYCARDIA, VENTRICULAR;

EID: 79961084413     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.247338     Document Type: Article

References (7)

1. Liu N, Ruan Y, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis. 2008;51:23-30. (Pubitemid 351965496)
2. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380-383.
3. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, Piston DW, Huke S, Knollmann BC. Flecainide inhibits arrhythmogenic Ca2 + waves by open state block of ryanodine receptor Ca2 + release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol. 2010;48:293-301.
4. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99:292-298. (Pubitemid 44174937)
5. Eisner DA, Choi HS, Diaz ME, O'Neill SC, Trafford AW. Integrative analysis of calcium cycling in cardiac muscle. Circ Res. 2000;87:1087-1094.
6. Liu H, Atkins J, Kass RS. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol. 2003;121:199-214. (Pubitemid 36292990)
7. Amerini S, Carbonin P, Cerbai E, Giotti A, Mugelli A, Pahor M. Electrophysiological mechanisms for the antiarrhythmic action of mexiletine on digitalis-, reperfusion-and reoxygenation-induced arrhythmias. Br J Pharmacol. 1985;86:805-815. (Pubitemid 16211357)